Cellular Intelligence, an AI startup funded by Mark Zuckerberg, has acquired the rights to an experimental Parkinson's cell therapy from Novo Nordisk, the pharmaceutical company known for Ozempic. This acquisition signifies a convergence of artificial intelligence and biotechnology in the pursuit of treatments for neurological diseases. The deal involves Cellular Intelligence taking over the development and treatment rights for the therapy. AI
影响 This acquisition highlights the growing trend of AI companies entering the biopharmaceutical space to accelerate drug discovery and development for complex diseases.
排序理由 Acquisition of a late-stage therapeutic asset by an AI-focused company.
在 Mastodon — sigmoid.social 阅读 →
AI 生成摘要 · Google Gemini · 来自 2 个来源。 我们如何撰写摘要 →
